A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

ClinicalTrials.gov ID: NCT01643408

Public ClinicalTrials.gov record NCT01643408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.

Study identification

NCT ID: NCT01643408
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Jazz Pharmaceuticals; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

asparaginase Erwinia chrysanthemi Drug

Drug

Eligibility (public fields only)

Age range: 1 Year to 30 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2012
Primary completion: Jul 31, 2013
Completion: Nov 30, 2013
Last update posted: Jun 22, 2021

2012 – 2013

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
Children's Hospital of Los Angeles	Los Angeles	California	90027	—
Children's Hospital of Orange County	Orange County	California	92868	—
Stanford Medical Center	Palo Alto	California	94304	—
Children's Hospital	Aurora	Colorado	80045	—
All Children's Hospital	St. Petersburg	Florida	33701	—
Children's Memorial Hospital	Chicago	Illinois	60611	—
John Hopkins	Baltimore	Maryland	21231	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
University of Minnesota	Minneapolis	Michigan	55455	—
Children's Hospital and Clinics of Minnesota	Minneapolis	Minnesota	55406	—
UMDNJ/Robert Wood Johnson	New Brunswick	New Jersey	08903	—
Columbia Presbyterian Medical Center	New York	New York	10032	—
Montifiore Medical Center	The Bronx	New York	10467	—
Oregon Health & Sciences	Portland	Oregon	97239	—
Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania	15224	—
Texas Children's Hospital	Houston	Texas	77030	—
Inova Fairfax Medical Center	Falls Church	Virginia	22042	—
Children's Hospital of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01643408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2021 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01643408 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →